Telomir Pharma Announces New Preclinical Data Showing That Lead Oral Drug Candidate, Telomir-1, Reverses Multiple Hallmarks Of Cellular Decline Across Several Human Cell Lines

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced new preclinical data showing that its lead oral drug candidate, Telomir-1, reverses multiple hallmarks of cellular decline across several human cell lines. The findings include improved mitochondrial activity, reduced oxidative stress, restored calcium balance, and protection from toxic metal effects-offering a mechanistic foundation for the Company's new research initiatives in autism spectrum disorder (ASD) and spasmodic dysphonia (SD).

The in vitro studies, conducted in collaboration with SmartAssays, demonstrated Telomir-1's ability to:

Improve cell viability under stress, particularly in dividing cell populations.
Maintaining cell survival is critical for tissue repair, immune defense, and slowing the progression of degenerative conditions.

Boost mitochondrial function, indicating stronger energy production.
Healthy mitochondria are essential for powering cells and preventing energy loss that drives aging and diseases like Alzheimer's, Parkinson's, and autism.

Reduce reactive oxygen species (ROS), limiting oxidative damage.
Excess ROS contributes to DNA damage, inflammation, neurodegeneration and cell death, all of which accelerate aging and chronic diseases.

Restore calcium signaling, helping maintain healthy cellular functions and communication.
Disrupted calcium balance impairs brain, muscle, and heart function and is a known trigger of cellular death and neurodegeneration.

Protect cells from metal-induced toxicity, including iron and copper-both linked to ROS formation, calcium dysregulation and accelerated cellular aging and death.
Iron and copper accumulation drive oxidative stress and mitochondrial failure.